Biotech News Collection: 30 Best & Worst Stocks to Watch
Cytokinetics, Inc. (NASDAQ:CYTK) was the leading gainer in the biotechnology industry as it is still testing their drug tirasemtiv, although Biogen Idec Inc. (NASDAQ:BIIB) stopped development of Lou Gehrig’s Disease drug.
Oncothyreon Inc (USA) (NASDAQ:ONTY) jumped 9.13% on Form SC 13G/A, signifiying that Antipodean Domestic Partners (a prior 5% shareholder) has sold out completely and has no stake in the company.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) rallied a day after investigational compound for RenaZorb demonstrated positive, statistically significant data in a phase I trial in healthy volunteers.
Celsion Corporation (NASDAQ:CLSN) gained sharply as the launch of its ThermoDox in 2014 will reportedly be driving the market forward.
Pacific Biosciences of California (NASDAQ:PACB) traded higher after a report claimed that its Single Molecule, Real-Time (SMRT) technology will be used in a key study conducted by the U.S. Food and Drug Administration, Aligent Technologies (NYSE:A) , and UC Davis.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) advanced on a collaboration with Pfizer Inc. (PFE) to develop almost six injectable medicines.
Exelixis, Inc. (NASDAQ:EXEL) increased after CEO presentation at J.P. Morgan 31st Annual Healthcare Conference.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), ImmunoGen, Inc. (NASDAQ:IMGN), Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), Incyte Corporation (NASDAQ:INCY) and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) all gained above 2%.
On the other hand, below 2% rally was seen for NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), Inovio Pharmaceuticals, Inc. (NYSEAMEX:INO), PDL BioPharma Inc. (NASDAQ:PDLI) and Celgene Corporation (NASDAQ:CELG).
On the flip side, Cell Therapeutics Inc (NASDAQ:CTIC) lost the most among biotech stocks after news of opening Phase 3 Trial enrollment for Pacritinib.
Peregrine Pharmaceuticals (NASDAQ:PPHM) declined after the Tustin-based drug developer said bavituximab affected one-milligram doses.
Sequenom, Inc. (NASDAQ:SQNM) lost 6% after Law360 reported the company has requested a Federal Circuit panel to bar its competitor from selling a noninvasive prenatal blood test.
Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) was another big loser after saying that FDA needs additional time to review Hep C Drug.
Sarepta Therapeutics Inc (NASDAQ:SRPT) fell before its presentation at the 31st Annual JP Morgan healthcare Conference in San Francisco. See few highlights here.
Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) traded down after providing business update.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped more than 2% while Savient Pharmaceuticals, Inc. (NASDAQ:SVNT), Neostem Inc. (NYSEAMEX:NBS), Neostem Inc. (NYSEAMEX:NBS) and Galena Biopharma Inc (NASDAQ:GALE) each saw a correction of less than 2%.
Surprisingly, VIVUS, Inc. (NASDAQ:VVUS) and YM BioSciences Inc. (USA) (NYSEAMEX:YMI) recorded no change on Wednesday.
Leave a Reply